Table 2.

EPC changes over twelve weeks of telmisartan therapy.

	Median # per 105 PBMC (IQR)
Total Absolute EPCs	Week 0	Week 6	6-Week Fold Change	p	Week 12*†	12-Week Fold Change	p
Glycophorin−/CD133+/KDR+	8.0 (2.7, 112.4)	82.8 (11.3, 188.2)	1.8	0.02	89.2 (17.6, 159.9)	1.7	0.08
CD34+/CD133+	33.3 (13.4, 85.5)	67.2 (31.6, 121.8)	1.4	0.06	87.6 (31.2, 128.5)	1.8	0.006
CD34+/KDR+	1.8 (0.8, 49.6)	39.5 (2.0, 85.2)	1.9	0.08	45.9 (4.1, 77.6)	1.9	0.03
CD34+/CD133+/KDR+	0.9 (0.3, 48.0)	38.5 (1.6, 83.9)	2.0	0.04	44.1 (3.0, 74.6)	2.0	0.02
Within CD34+ EPC Subset	% of CD34+ EPC (IQR)
CD133+	34.9 (32.5, 46.4)	37.6 (31.7, 43.1)	1.0	0.91	36.4 (25.3, 41.7)	1.0	0.83
KDR+	5.9 (1.7, 17.4)	14.8 (2.6, 26.0)	1.5	0.11	14.5 (4.9, 20.8)	1.4	0.43
CD133+/KDR+	4.2 (0.4, 15.2)	14.4 (2.4, 25.4)	1.7	0.07	14.1 (3.1, 19.8)	1.6	0.29

^*One subject excluded for increasing statin dose between weeks 6 and 12

^†12 subjects off drug

EPC= Endothelial Progenitor Cells, IQR=Interquartile Range, PBMC= Peripheral Blood Mononuclear Cells